Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
December 02, 2024 07:30 ET
|
Profound Medical Corp.
– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – ...
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
November 04, 2024 06:55 ET
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
October 16, 2024 16:15 ET
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Profound Medical Announces Second Quarter 2024 Financial Results
August 08, 2024 16:05 ET
|
Profound Medical Corp.
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
July 18, 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...